Aqsens Health sharpens its focus around urinary tract diseases and starts looking into possibilities in the well-being sector.
Aqsens Health has decided to concentrate the company’s research on urine-based analysis, venturing further into the diagnostics of urologic and urinary tract conditions and well-being applications.
After thorough research studies and market analyses, the company's board of directors has decided to focus research efforts on two biological matrices – urine and saliva. This sharpened focus will enable the company to deepen its understanding of the changes in the human metabolism caused by severe urinary tract diseases. In addition, Aqsens Health will start exploring business opportunities in the well-being sector.
“As we have conducted thousands of saliva, urine and fecal sample measurements, it has become clear that urine and saliva deliver the best results with our novel combination of phages and E-TRF. Urine especially, because it has less microbial activity compared to for example feces,” says Chief Scientific Officer Janne Kulpakko.
“This sharper focus will not only allow us to develop tests to detect cancers like prostate, bladder or kidney, but also infections or for example kidney stones or the early signs of renal failure,” he continues.
“When we analyzed our business opportunities and discussed with potential partners and customers, we concluded that urine as a sample matrix provides an attractive opportunity because it’s much more stable than saliva or feces. Sampling can be done at home and the sample can be sent to a laboratory for analysis by standard mail,” explains CEO Timo Teimonen.
“This sharpened focus opens several new business possibilities with potential partners, and I think it will enable us to become the leading company in understanding urine and metabolic changes in it, be it a health related disorder test, a well-being related test, or self-monitoring of different health parameters” Teimonen concludes.
This means that in the future Aqsens Health will direct collaborative activities to urine and saliva-based research. The next saliva-based research projects on malaria, tuberculosis and cholera are already planned with the Noguchi Memorial Institute for Medical Research in Ghana.
For more information, contact:
CEO and Co-Founder
Timo Teimonen
+358 40 5853105
timo.teimonen@aqsens.com
Aqsens Health Oy is a Finnish health- and biotechnology startup developing non-invasive screening tests for high-impact diseases. The company’s current focus is on establishing reliable and cost-efficient urine and saliva-based screening tests for urologic and urinary tract conditions and different infectious diseases, and developing a mobile screening platform fit for the needs of developing economies. The tests use Aqsens Health’s novel E-TRF technology in combination with phage-biosensors. The company’s laboratories and main office are located in Turku, Finland, with another office in the capital Helsinki.
